Nifty
Sensex
:
:
10817.60
36436.80
-185.90 (-1.69%)
-686.23 (-1.85%)

Pharmaceuticals & Drugs

Rating :
66/99  (View)

BSE: 532523 | NSE: BIOCON

228.05
-2.80 (-1.21%)
17-Sep-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  231.95
  •  234.00
  •  226.30
  •  230.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2059261
  •  4696.14
  •  359.00
  •  211.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 27,684.00
  • 27.91
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 29,049.80
  • 0.22%
  • 4.22

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 1.83%
  • 11.82%
  • FII
  • DII
  • Others
  • 1.26%
  • 3.01%
  • 21.41%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.82
  • 12.28
  • 12.32

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.45
  • 14.90
  • 7.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 12.70
  • 14.93

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.65
  • 25.97
  • 44.73

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.73
  • 4.50
  • 5.64

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.68
  • 20.92
  • 26.58

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
1,465.90
1,123.80
30.44%
1,528.80
1,169.50
30.72%
1,540.80
1,057.90
45.65%
1,321.00
968.60
36.38%
Expenses
1,028.40
886.00
16.07%
1,125.80
936.50
20.21%
1,160.10
836.20
38.73%
981.40
786.30
24.81%
EBITDA
437.50
237.80
83.98%
403.00
233.00
72.96%
380.70
221.70
71.72%
339.60
182.30
86.29%
EBIDTM
29.85%
21.16%
26.36%
19.92%
24.71%
20.96%
25.71%
18.82%
Other Income
24.10
68.80
-64.97%
28.20
67.50
-58.22%
25.60
33.90
-24.48%
54.40
50.80
7.09%
Interest
16.60
17.60
-5.68%
15.90
16.90
-5.92%
18.60
14.70
26.53%
18.80
13.80
36.23%
Depreciation
124.20
99.10
25.33%
119.80
95.30
25.71%
116.70
97.40
19.82%
112.20
93.60
19.87%
PBT
320.80
189.90
68.93%
295.50
188.30
56.93%
276.80
143.50
92.89%
451.80
125.70
259.43%
Tax
85.20
52.10
63.53%
40.90
40.70
0.49%
46.10
36.10
27.70%
73.20
42.50
72.24%
PAT
235.60
137.80
70.97%
254.60
147.60
72.49%
230.70
107.40
114.80%
378.60
83.20
355.05%
PATM
16.07%
12.26%
16.65%
12.62%
14.97%
10.15%
28.66%
8.59%
EPS
1.72
2.00
-14.00%
1.78
2.17
-17.97%
3.62
1.53
136.60%
5.91
1.15
413.91%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
5,856.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
Net Sales Growth
35.57%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
 
Cost Of Goods Sold
1,887.20
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
Gross Profit
3,969.30
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
GP Margin
67.78%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
Total Expenditure
4,295.70
4,120.70
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
Power & Fuel Cost
-
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
% Of Sales
-
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
Employee Cost
-
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
% Of Sales
-
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
Manufacturing Exp.
-
451.30
335.70
391.50
320.90
81.20
62.90
95.20
113.20
81.60
68.63
% Of Sales
-
8.18%
8.14%
10.06%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
General & Admin Exp.
-
53.00
56.80
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
% Of Sales
-
0.96%
1.38%
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
Selling & Distn. Exp.
-
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
% Of Sales
-
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
Miscellaneous Exp.
-
37.20
47.40
41.00
30.10
72.70
61.80
52.90
256.70
940.80
56.49
% Of Sales
-
0.67%
1.15%
1.05%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
EBITDA
1,560.80
1,393.70
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
EBITDA Margin
26.65%
25.27%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
Other Income
132.30
144.40
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
Interest
69.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
Depreciation
472.90
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
PBT
1,344.90
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
Tax
245.40
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
Tax Rate
18.25%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
PAT
1,099.50
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
PAT before Minority Interest
999.40
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
Minority Interest
-100.10
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
PAT Margin
18.77%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
PAT Growth
130.99%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
 
Unadjusted EPS
13.03
15.30
6.31
10.39
28.04
24.87
21.09
25.99
17.27
18.79
15.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
Share Capital
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
5,720.80
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
Non-Current Liabilities
2,123.20
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
Secured Loans
1,539.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
Unsecured Loans
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
Long Term Provisions
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
Current Liabilities
3,037.60
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
Trade Payables
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
Other Current Liabilities
1,373.80
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
Short Term Borrowings
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
Short Term Provisions
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
Total Liabilities
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
Net Block
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
Gross Block
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
Accumulated Depreciation
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
Non Current Assets
7,044.90
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
Capital Work in Progress
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
Non Current Investment
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
Long Term Loans & Adv.
401.50
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
0.00
Other Non Current Assets
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
0.00
Current Assets
4,822.80
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
Current Investments
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
Inventories
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
Sundry Debtors
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
Cash & Bank
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
Other Current Assets
612.90
373.30
395.80
73.60
171.60
157.60
136.90
114.30
56.70
136.10
Short Term Loans & Adv.
46.40
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
120.28
Net Current Assets
1,785.20
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
Total Assets
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,154.60
662.10
640.00
526.40
210.70
560.70
471.20
564.10
798.50
443.81
PBT
1,214.90
610.00
849.70
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
Adjustment
260.30
355.70
204.40
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
Changes in Working Capital
-29.10
-106.50
-211.10
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
Cash after chg. in Working capital
1,446.10
859.20
843.00
773.20
344.10
709.40
565.20
638.00
879.80
476.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-291.50
-197.10
-203.00
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-713.80
-684.00
-498.50
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
Net Fixed Assets
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
Net Investments
184.70
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
Others
-617.90
-195.40
-203.30
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
Cash from Financing Activity
-241.70
-239.70
-177.50
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
Net Cash Inflow / Outflow
199.10
-261.60
-36.00
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
Opening Cash & Equivalents
449.00
710.20
757.50
462.60
557.00
474.00
369.00
359.00
139.90
11.81
Closing Cash & Equivalent
659.30
449.00
710.20
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
50.17
85.19
79.49
67.22
53.86
48.42
43.18
36.31
32.49
28.25
ROA
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
ROE
18.00%
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
ROCE
16.10%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
Fixed Asset Turnover
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
Receivable days
77.96
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
Inventory Days
58.05
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
Payable days
86.75
87.96
78.68
68.27
58.15
55.73
65.24
70.25
70.62
41.52
Cash Conversion Cycle
49.26
58.09
50.48
65.60
70.42
62.29
62.99
81.79
100.29
71.30
Total Debt/Equity
0.40
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
Interest Cover
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81

News Update


  • Biocon signs agreement with China Medical System Holdings’ arm
    13th Sep 2019, 09:56 AM

    The company has signed License and Supply Agreement for three Generic Formulation products in Greater China

    Read More
  • Biocon’s arm receives certificate of GMP compliance
    22nd Aug 2019, 09:01 AM

    This approval expands the company’s capacities multi-fold with the new large scale devices facility

    Read More
  • Biocon, Mylan launch Ogivri in Australia
    1st Aug 2019, 14:12 PM

    Ogivri is the first trastuzumab biosimilar approved and launched in Australia

    Read More
  • Biocon reports 72% rise in Q1 consolidated net profit
    26th Jul 2019, 14:48 PM

    Total income of the company increased by 24.94% at Rs 1490.00 crore for Q1FY20

    Read More
  • Biocon - Quarterly Results
    25th Jul 2019, 18:18 PM

    Read More
  • USFDA completes inspection at Biocon’s Insulins facilities in Malaysia
    8th Jul 2019, 09:25 AM

    The inspection across these 3 units concluded with 12 observations issued on the Form 483

    Read More
  • Biocon to sell BFI Business to Biocon Biologics
    18th Jun 2019, 08:58 AM

    The Board of Directors of the Company at its meeting held on June 17, 2019 has approved the same

    Read More
  • Biocon receives EU GMP Certification for Biologics facilities in Bengaluru
    14th Jun 2019, 14:17 PM

    These facilities, used for the manufacture of company’s portfolio of biosimilars, were inspected by the European agency in March 2019

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.